Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Orlistat.

N N Wong¹, A Cheng-Lai

¹Department of Pharmacy and Family Medicine, Montefiore Medical Center, 111 East 210th Street, Bronx, NY 10467, USA.

Heart Disease (Hagerstown, Md.)

|December 1, 2001

Summary

This summary is machine-generated.

Orlistat, a lipase inhibitor, aids significant weight loss and prevents weight regain in obese patients. It also improves cardiovascular risk factors, with manageable gastrointestinal side effects.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A comparison of direct thrombin inhibitors in the treatment of Heparin-Induced Thrombocytopenia: a single institution experience.

Journal of thrombosis and thrombolysis·2008

Same author

Colesevelam: a new bile acid sequestrant.

Heart disease (Hagerstown, Md.)·2002

Same author

Aggrenox: an aspirin and extended-release dipyridamole combination.

Heart disease (Hagerstown, Md.)·2002

Same author

Cerivastatin.

Heart disease (Hagerstown, Md.)·2001

Same author

Cardiovascular drug therapy in the elderly.

Heart disease (Hagerstown, Md.)·2001

Same author

Rosiglitazone: an agent from the thiazolidinedione class for the treatment of type 2 diabetes.

Heart disease (Hagerstown, Md.)·2001

Same journal

Ximelagatran: a new oral anticoagulant.

Heart disease (Hagerstown, Md.)·2003

Same journal

Long-term (2-4 year) weight reduction with metformin plus carbohydrate-modified diet in euglycemic, hyperinsulinemic, midlife women (Syndrome W).

Heart disease (Hagerstown, Md.)·2003

Same journal

A comparison of humanistic qualities among medical students, residents, and faculty physicians in internal medicine.

Heart disease (Hagerstown, Md.)·2003

Same journal

Effect of carotid angioplasty-stenting on short-term mortality and stroke.

Heart disease (Hagerstown, Md.)·2003

Same journal

Evidence for the extrapulmonary localization of inhaled nitric oxide.

Heart disease (Hagerstown, Md.)·2003

Same journal

Timing and duration of administration are crucial for antiinfarct effect of AMP 579 infused at reperfusion in rabbit heart.

Heart disease (Hagerstown, Md.)·2003

See all related articles

Area of Science:

Pharmacology
Gastroenterology
Cardiology

Background:

Obesity is a significant risk factor for cardiovascular disease.
Orlistat is a lipase inhibitor used for obesity management.
Unlike appetite suppressants, Orlistat reduces dietary fat absorption.

Purpose of the Study:

To assess the effects of Orlistat on weight loss and regain.
To evaluate Orlistat's impact on obesity-related risk factors.
To determine the safety and tolerability of Orlistat.

Main Methods:

Large-scale clinical trials of 1-2 years' duration.
Comparison of Orlistat plus hypocaloric diet versus placebo plus hypocaloric diet.
Monitoring of weight changes, cardiovascular risk factors, and adverse events.

Related Experiment Videos

Main Results:

Significantly more patients achieved 5-10% weight loss with Orlistat compared to placebo in year one.
Orlistat treatment led to less weight regain in the second year.
Favorable effects observed on blood pressure, serum lipids, glucose, and insulin levels.
Most common adverse events were gastrointestinal, mild-to-moderate, and decreased over time.

Conclusions:

Orlistat is effective for weight loss and preventing weight regain in obese patients.
Orlistat improves key obesity-related cardiovascular risk factors.
Gastrointestinal side effects are common but generally manageable and transient.